Funding
This study was supported by the Complex Program of Basic Research under the Siberian Branch of the Russian Academy of Sciences within the Basic Research Topic of Research Institute for Complex Issues of Cardiovascular Diseases № 05462015-0012 "Atherosclerosis and its comorbidities. Features of diagnostics and risk management in a large industrial region of Siberia"
Конфликт интересов
Авторы заявляют об отсутствии конфликта интересов.
Conflict of Interest
1. The authors declare that there is no conflict of interest regarding the publication of this article.
2. Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arq Bras Cardiol. 2016; 106 (1): 62-69.
3. Lukaszewski M, Kosiorowska K, Kaminska D, Obremska M, Mazanowska O, Krajewska M. Myocardial remodeling after kidney transplantation: a case report. BMC Nephrol. 2018; 19 (1): 372.
4. Lai YC, Li N, Lawrence W, Wang S, Levine A, Burchhardt DM, et al. Myocardial remodeling and susceptibility to ventricular tachycardia in a model of chronic epilepsy. Epilepsia Open. 2018; 3 (2): 213-223.
5. Hassell ME, Vlastra W, Robbers L, Hirsch A, Nijveldt R, Tijssen JG, et al. Long-term left ventricular remodelling after revascularisation for ST-segment elevation myocardial infarction as assessed by cardiac magnetic resonance imaging. Open Heart. 2017; 4 (1): e000569.
6. Galli A, Lombardi F. Postinfarct Left Ventricular
7. Remodelling: A Prevailing Cause of Heart Failure. Cardiol Res Pract. 2016; 2016: 2579832.
8. Ali SR, Ranjbarvaziri S, Talkhabi M, Zhao P, Subat A, Hojjat A, et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ Res. 2014; 115 (7): 625-635.
9. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac Fibrosis: The Fibroblast Awakens.
10. Circ Res. 2016; 118 (6): 1021-1040.
11. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014; 71 (4): 549-574.
12. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007; 87 (4): 1285-1342.
13. Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018; 68-69: 490-506.
14. Bowers SL, Banerjee I, Baudino ТА. The extracellular matrix: at the center of it all. J Mol Cell Cardiol. 2010; 48 (3): 474-482.
15. Ruddy JM, Ikonomidis JS, Jones JA. Multidimensional
16. Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vase Res. 2016; 53 (1-2):1-16.
17. Liu CY, Heckbert SR, Lai S, Ambale-Venkatesh B, Ostovaneh MR, McClelland RL, et al. Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2017; 70 (25): 3102-3109.
18. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J. 2006; 70: 1379-1384.
19. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodeling and prognosis after acute myocardial infarction. Eur Heart J. 2008; 29 (17). 2116-2124.
20. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-brain natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002; 106 (23): 2913-2918.
21. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is independent prognostic factor in stable coronary artery disease. Eur J Clin Invest. 2005; 35 (9): 537-545.
22. Berezin AYe, Samura ТА. Prognostic potential of matrix metalloproteinase 3, matrix metalloproteinase 9, and brain natriuretic peptide in patients who have had Q myocardial infarction. Ukrainian Therapeutic Journal. 2012; (1): 43-51. Russian (Березин A.E, Самура ТА. Прогностический потенциал матриксной металлопротеиназы 3, матриксной металлопротеиназы 9 и мозгового натрийуретического пептида у пациентов, перенесших Q инфаркт миокарда // Укр. терапевт, жури. 2012. № 1. С. 43-51).
23. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail. 2004; 10 (4): 328-333.
24. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J. 2007; 28 (6): 711-718.
25. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and allcause mortality after acute myocardial infarction. EurJ Heart Failure. 2008; 10 (2): 133-139.
26. Chu JW, Jones GT, Tarr GP, Phillips LV, Wilkins GT, van RijAM, et al. Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. Int J Cardiol. 2013. 167 (4): 1242-1246.
27. Bagriy AE, Chumachenko NV, Tsyba NYu, Babina TV. Evaluation of plasma levels of MMP-2 and MMP-9 in predicting left ventricular remodeling in patients with acute myocardial infarction with ST elevation. Nutrition Experimental and Clinical Medicine: Donetsk, 2010. 1 (14): 23-26. Russian (Багрий А.Э., Чумаченко H.B., Цыба H. Ю., Бабина Т.В. Оценка плазменных уровней ММП-2 и ММП-9 в прогнозировании ремоделирования левого желудочка у больных с острым инфарктом миокарда с элевацией ST // Питания експериментальной та кл1н1чной медицини: сб. ст. Донецк, 2010. T. 1, вып. 14. С. 23-26).
28. Atik T, Durmaz B, Yorganci OU, Cogulu O, Kioutsouk M, Ozkinay F. Changes of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 during left ventricular remodeling in acute myocardial infarction patients after percutaneous coronary intervention. Biomed Res. 2013; 24 (2): 179-184.
29. Cogni AL, Farah E, Minicucci MF, Azevedo PS, Okoshi K, Matsubara BB, et al. Metalloproteinases-2 and -9 predict left ventricular remodeling after myocardial infarction. Arq Bras Cardiol. 2013; 100 (4): 315-321.
30. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Antelli A, et al. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004; 43 (11): 2000-2008.